Merge PACS vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Merge PACS
by Merative
VS
EchoNext
by Pathway Labs

AI Verdict

Merge PACS is an enterprise-level Picture Archiving and Communication System (PACS) that integrates AI for streamlined radiology and cardiology imaging workflows, offering comprehensive image management and customizable worklists. EchoNext, on the other hand, is a specialized AI tool focused on analyzing standard ECGs to detect hidden structural heart disease. While both operate in the Cardiology AI space and are FDA-cleared, Merge PACS provides a broad imaging infrastructure with AI integration capabilities, whereas EchoNext is a specific diagnostic AI application for early heart disease detection.

Choose Merge PACS if…

Choose Merative Merge PACS if your health system requires an enterprise-level solution to consolidate imaging data, streamline radiology workflows across multiple sites, and integrate various AI applications into a single worklist. It is ideal for organizations needing flexible deployment options (on-premise, cloud, hybrid) and advanced diagnostic tools for multi-modality interpretation, including mammography and image fusion.

View Merge PACS →

Choose EchoNext if…

Choose EchoNext if you need an FDA-cleared AI tool to non-invasively screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. It is best suited for broad deployment across various clinical settings, from major hospitals to community practices, to identify at-risk patients who may require further cardiac evaluation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Merge PACS EchoNext
Pricing Contact vendor Starts at $600/month
Deployment On-premise, Cloud, Hybrid Available through the OpenEvidence clinical decision support platform.
BAA Available Unknown Yes AI-estimated
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Merge PACS

Merge PACS emphasizes customizable and intuitive workflows, including a modernized Real Time Worklist and features like Synchronized Priors Scrolling for mammography, designed to reduce clicks and improve efficiency for radiologists [1, 4, 5, 9]. EchoNext, while integrated into the OpenEvidence platform, is a more specialized tool for ECG analysis, and its usability is primarily tied to that integration rather than a comprehensive workflow solution [30].

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI, and has been validated in multiple studies [2, 3, 6, 7, 12, 28, 29, 31]. It has received FDA clearance for six indications and has been credited with leading to the first AI-triggered heart transplant [6, 8, 32]. Merge PACS offers AI integration and enhanced diagnostic workflows across various modalities, but the specific clinical impact and comparative accuracy of its integrated AI tools are not as explicitly detailed or as groundbreaking as EchoNext's specialized capability [3, 11, 14].

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, making it easier for potential customers to understand the investment [Tool B]. Merge PACS requires contacting the vendor for pricing details, which can be a barrier to initial assessment of value [Tool A]. While Merge PACS is an enterprise-level system with broad capabilities, EchoNext's clear pricing structure provides more immediate value transparency.

Enterprise Readiness

Merge PACS

Merge PACS is explicitly designed as an enterprise-level PACS, supporting multi-site health systems, offering flexible deployment options (on-premise, cloud, hybrid), and integrating with various hospital systems like EMR/EHR, RIS, HIS, and VNA [Tool A, 11, 13]. EchoNext is available through the OpenEvidence platform and is designed for broad access, but its enterprise readiness is primarily through this platform integration rather than being a standalone enterprise imaging solution [Tool B, 30].

Innovation

EchoNext

EchoNext represents a significant innovation as the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, outperforming human cardiologists in diagnostic accuracy [2, 3, 6, 8, 10, 12, 29, 31]. This addresses a critical gap in early detection of heart disease. Merge PACS focuses on integrating third-party AI and enhancing existing radiology workflows, which is innovative, but EchoNext's core functionality is a novel diagnostic breakthrough [1, 3, 11, 14].

Support & Docs

Merge PACS

Merative, the company behind Merge PACS, provides a Merge Community Hub, webinars, and phone support with regional numbers, indicating a structured and comprehensive support system [15]. While EchoNext is integrated into the OpenEvidence platform, specific details about its direct support and documentation from Pathway Labs are not as readily available, relying more on the OpenEvidence platform's existing support [Tool B, 30].

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Merge PACS EchoNext
Tool Name Merge PACS EchoNext
Company Merative Pathway Labs
Description An enterprise-level Picture Archiving and Communication System (PACS) that streamlines radiology workflows, consolidates imaging data, and integrates AI insights across multi-site health systems. It supports multi-modality diagnostic interpretation with flexible deployment options. An FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories Cardiology AI, Radiology & Imaging AI Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Key Features AI integration and readiness (single worklist access to 3rd party AI applications); Customizable, composite worklist for multiple specialties; Cloud-ready architecture (on-premise, cloud, hybrid deployment options); Enhanced diagnostic workflows (e.g., Synchronized Priors Scrolling for mammography, image fusion); Real-time analytics and dashboards (Merge Dashboards); Enterprise-wide image management and consolidation; Integration with EMR/EHR, RIS, HIS, and VNA systems; Secure web-based access for remote reading AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring Merge PACS and EchoNext.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Merge PACS is designed to improve reading workflows across the enterprise, integrating with EMR/EHR, RIS, HIS, and VNA systems to consolidate imaging data and provide a single AI-driven workspace. [1, 16, 19, 22, 23] EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, and its AI-powered ECG analysis is intended to flag patients at high risk for structural heart disease, prompting further evaluation with an echocardiogram. [11, 13, 31]
Merge PACS enhances diagnostic workflows with features like synchronized priors scrolling for mammography and image fusion, and AI integration is designed to improve diagnostic accuracy, with some studies showing improvements up to 93.2% in early tumor detection. [3, 8, 18, 23, 34] EchoNext has demonstrated high accuracy in detecting structural heart disease, achieving an AUROC of 85.2% in internal tests and 78-80% in external validation, and in studies, it outperformed cardiologists in identifying structural heart problems from ECGs alone. [2, 3, 4, 5, 6, 28]
Merge PACS aims for a responsive and clinically intuitive viewer with ongoing usability enhancements, and previous versions have been noted to have a small learning curve for cardiologists. [7, 8] EchoNext analyzes standard ECGs, which are routine tests, suggesting that the learning curve for interpreting its risk scores would primarily involve understanding the implications of the AI's findings for further patient management. [2, 11, 13, 31]
While specific details on support quality are limited, Merge PACS is described as having good daytime support, though after-hours issues may require escalation. [17] EchoNext is offered through the OpenEvidence platform, which aims to make the breakthrough in heart disease detection available broadly, implying support for its integration and use in various clinical settings. [11]
Merge PACS is an enterprise-level system that supports multi-site health systems, offering cloud-ready architecture and enterprise-wide image management and consolidation. [10, 14, 18, 25] EchoNext is designed for broad access, from major hospitals to community practices, and its deployment through the OpenEvidence platform suggests a scalable approach for wider adoption. [11]
Merge PACS facilitates communication of critical results with optional, configurable components, and the system automatically records all communications, ensuring a fully compliant audit trail. [23, 26] The provided information for EchoNext does not explicitly detail its audit-trail features, but as a clinical decision support tool, robust logging of its recommendations and user interactions would be a standard expectation for accountability.
Merge PACS emphasizes regulatory-grade security, including encryption to protect sensitive patient data, and features heightened cybersecurity in its latest versions. [1, 18] While the provided information for EchoNext does not detail security measures beyond HIPAA compliance, as an FDA-cleared AI tool handling sensitive patient data, it would be expected to adhere to stringent security protocols to safeguard patient information.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Merge PACS or EchoNext

Backers

Who funded each tool's parent company.

Merge PACS

AI Tool Finder
AI-powered search. Results may not be comprehensive.